Tolvaptan Accord 7.5 mg Tablet
Authorisation EU/1/23/1719/001-004 · Accord Healthcare S.L.U.
- Licence holder
- Accord Healthcare S.L.U. (all products →)
- Active substance
- Tolvaptan
- Clinical trials
- 2 clinical trials →
- Dosage form
- Tablet
- Route of administration
- Oral use
- ATC code
- C03XA01
- First authorised
- 24/03/2023
- Prescription status
- Product subject to prescription which may not be renewed (A)
- Supply
- Supply through pharmacies only
- Legal basis
- Generic application (Article 10(1) of Directive No 2001/83/EC)
Tolvaptan: supply and approvals
11 authorised products on the HPRA list contain Tolvaptan. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.
- EU shortage (EMA)
- No entry in the EMA shortage catalogue (checked 21 Nov 2026)
- US shortage (FDA)
- No entry in the FDA drug shortage list (checked 21 Nov 2026)
- Germany (BfArM)
- No entry in the BfArM supply notices (checked 21 Nov 2026)
Registers: EU shortages · US shortages · German shortages · EMA approvals
About this licence
Centralised EU authorisation. This product holds an EU-wide marketing authorisation granted by the European Commission after assessment by the European Medicines Agency, valid in every EU country. Its EU product number is 1719. It has been authorised for 3 years (since 24 March 2023). The HPRA list does not say whether it is on sale.
Other medicines with Tolvaptan in Ireland
10 other products on the HPRA list contain Tolvaptan, from 3 licence holders; 0 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.
| Medicine | Licence holder | Licence | Status |
|---|---|---|---|
| Jinarc 15 mg tablets | Otsuka Pharmaceutical Netherlands B.V. | Centralised EU authorisation | Not stated |
| Jinarc 15 mg tablets + Jinarc 45 mg tablets | Otsuka Pharmaceutical Netherlands B.V. | Centralised EU authorisation | Not stated |
| Jinarc 30 mg tablets | Otsuka Pharmaceutical Netherlands B.V. | Centralised EU authorisation | Not stated |
| Jinarc 30 mg tablets + Jinarc 60 mg tablets | Otsuka Pharmaceutical Netherlands B.V. | Centralised EU authorisation | Not stated |
| Jinarc 30 mg tablets + Jinarc 90 mg tablets | Otsuka Pharmaceutical Netherlands B.V. | Centralised EU authorisation | Not stated |
| Samsca 15 mg Tablet | Otsuka Pharmaceutical Netherlands B.V. | Centralised EU authorisation | Not stated |
| Samsca 30 mg Tablet | Otsuka Pharmaceutical Netherlands B.V. | Centralised EU authorisation | Not stated |
| Tolvaptan Accord 15 mg tablets | Accord Healthcare S.L.U. | Centralised EU authorisation | Not stated |
| Tolvaptan Accord 30 mg tablets | Accord Healthcare S.L.U. | Centralised EU authorisation | Not stated |
| Tolvaptan Ascend 7.5 mg tablets | Ascend GmbH | National authorisation (PA) | Not marketed |
The licence holder
Accord Healthcare S.L.U. holds 181 products on the HPRA list, with 76 different active substances; 0 of the products are marked as marketed.
This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.
How this page is built
The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.
- HPRA Authorised Medicines List (open data) ↗ Licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status for this product
This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 22 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.